Kurt Christensen, PhD

2025 Preventive genomic services: trial- and model-based approaches to estimating health and economic outcomes. ISPOR Annual Meeting, Montreal, Canada.

2025 Benefits and cost-effectiveness of cascade testing for hypertrophic cardiomyopathy (Selected Oral Abstract). Annual Meeting of the Society for Medical Decision Making, Ann Arbor, MI.

2024 Moderator, technology for translation. ASHG Annual Meeting, Denver, CO.

2024 Global perspectives on implementing clinical genomic sequencing equitably, effectively and efficiently. ELSI Congress, New York, NY.

2024 Preventive genomic testing: is it worth the cost? Vanderbilt University Medical Center Genomics and Personalized Medicine Seminar Series, Nashville, TN.

2024 Genomic testing of healthy patients. Decision Science Methods Club, Erasmus MC, Netherlands (Web-based meeting).

2023 Preemptive CYP2C19 genotyping to inform P2Y12 inhibitor therapy: real world outcomes data from Sanford Health (Selected Oral Abstract). Health Care Systems Research Network Annual Conference, Denver, CO.

2023 Cost effectiveness of newborn genetic screening for long QT syndrome (Selected Oral Abstract). ISPOR Annual Meeting, Boston, MA.

2022 Concordance with pharmacogenomic clinical decision support recommendations is high following preemptive pharmacogenomic testing (Selected Oral Abstract). ELSI Congress, Virtual Meeting.

2022 Population genetic screening: the impact of the Sanford Chip Program. International Precision Med Tri-Con, San Diego, CA.

2021 Benefits and cost-effectiveness of sibling cascade testing for pediatric cancer predisposition syndromes: findings from the PreEMPT Model (Selected Oral Abstract and Featured Plenary Presentation). ASHG Annual Meeting, Virtual Meeting.

2020 Will polygenic risk scores and preventive genomics deliver in precision medicine? University of Florida Precision Medicine Conference, Orlando, FL.

2019 Genomic screening: what's the value? Maine Medical Center Research Institute, Portland, ME.

2019 Evaluating the economic impact of genomic testing during clinical trials. ASHG Annual Meeting, Houston, TX.

2019 Impact of newborn genomic sequencing on short-term healthcare utilization and associated costs: preliminary findings from the BabySeq Project (Selected Oral Abstract). NHGRI Trainee Meeting, St. Louis, MO.

2019 Global developments in artificial intelligence and machine learning in healthcare. ISPOR Annual Meeting, New Orleans, LA.

2018 Medically reportable outcomes and cost implications of newborn sequencing in the BabySeq project. Frontiers in Pediatric Genomic Medicine Conference, La Jolla, CA.

2018 The science of surveys: interactive session on the foundations of survey design and implementation to improve genetic counselor research and clinical practice. Annual Meeting of the National Society of Genetic Counselors, Atlanta, GA.

2018 Empirical approaches to medical and economic outcomes in genomic medicine. Sanford Imagenetics Genomic Medicine Symposium, Sioux Falls, SD.

2018 Impact of disclosing genetic risk for Alzheimer’s disease to patients with mild memory problems (Selected Oral Abstract). GSA Annual Scientific Meeting, Boston, MA.

2017 How patients and providers respond to genomic testing. Cornell University, Ithaca, NY.

2017 The impact of integrating genome sequencing into the care of healthy patients. Cornell Center for Comparative and Population Genomics (3CPG), Ithaca, NY.

2017 Clinician Bake Off update. CSER Network Meeting, Bethesda, MD.

2017 Is genomic sequencing worth the costs? ACMG Annual Meeting, Phoenix, AZ.

2017 Cost analyses of genomic sequencing in healthy and sick populations. Steering Committee Meeting of the Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT) Program, La Jolla, CA.

2017 What REVEAL and MedSeq tell us about the future of precision medicine. American Academy of Neurology Annual Meeting, Boston, MA.

2017 Cost analyses of genomic sequencing in healthy and sick populations. Monthly meeting of the NSIGHT Steering Committee, Teleconference.

2017 Short-term costs of integrating whole genome sequencing into cardiology and primary care. World Precision Medicine Congress, Washington, DC.

2017 Short-term costs of whole genome sequencing in cardiology and primary care: findings from the MedSeq Project (Selected Oral Abstract). NHGRI Trainee Meeting, St. Louis, MO.

2016 MedSeq Project update: costs and outcomes of integrating whole genome sequencing into cardiology care. Invited seminar, Molecular and Population Genomics Program, Broad Institute of MIT and Harvard.

2016 Summary of NHGRI August 2016 payers meeting. Clinical Sequencing Exploratory Research Consortium (CSER) Network, Bethesda, MD.

2016 Managing secondary genomic findings. Festival of Genomics, Boston, MA.

2016 Highlights from the MedSeq Project. Healthcare and economic outcomes among primary care patients. CSER Network Meeting, Seattle, WA.

2015 Genomics in medicine: what will it take? Rhode Island College, Providence, RI.

2015 Responses of primary care physicians to unsolicited secondary findings about Lynch syndrome (Selected Oral Abstract). ASHG Annual Meeting, Baltimore, MD.

2015 Short-term costs of integrating genome sequencing into clinical care: preliminary results from the MedSeq Project (Selected Oral Abstract). ASHG Annual Meeting, Baltimore, MD.

2014 Patient perceptions about the utility of family history review during whole genome sequencing: initial findings from the MedSeq Study (Selected Oral Abstract). ASHG Annual Meeting, San Diego, CA.

2014 What is the long-term emotional and behavioral impact of genetic risk assessment for Alzheimer’s disease? Findings from the REVEAL Study (Selected Oral Abstract). Alzheimer’s Association International Conference, Copenhagen, Denmark.

2013 Short-term psychological benefits to consumer genetic testing: findings from the PGen Study (Selected Oral Abstract). APHA Annual Meeting, Boston, MA.

2013 The psychological impact of genetic risk information on individuals with mild cognitive impairment at imminent risk for conversion to Alzheimer’s disease dementia: findings from the REVEAL Study (Selected Oral Abstract). Alzheimer’s Association International Conference, Boston, MA.

2012 Changes to control perceptions following disclosure of APOE-coronary artery disease associations during genetic susceptibility testing for Alzheimer’s disease: Findings from the REVEAL Study (Selected Oral Abstract). ASHG Annual Meeting, San Francisco, CA.

2011 Genetic susceptibility testing for Alzheimer’s disease: what have we REVEALed? Baylor College of Medicine, Houston, TX.

2010 Genetic susceptibility testing for individuals at risk for Alzheimer’s disease: findings from the REVEAL Study (Selected Oral Abstract). GSA Annual Meeting, Atlanta, GA.

2010 How does pleiotropic information affect health behavior changes? Initial results from the REVEAL Study, a randomized trial of genetic testing for Alzheimer’s disease risk (Selected Oral Abstract). ACMG Annual Meeting, Albuquerque, NM.

2010 Perceived personal utility of Alzheimer’s disease genetic susceptibility testing and its influence on post-test responses: findings from the REVEAL Study (Selected Oral Abstract). Communications, Medicine and Ethics Conference, Boston, MA.

2010 The psychological impact of learning APOE ε4 increases the risk for cardiovascular disease during genetic risk assessment for Alzheimer’s disease: findings from the REVEAL Study (Selected Oral Abstract). International Conference on Alzheimer’s Disease, Honolulu, HI.

2009 Black and white Americans’ understandings of genetics (Selected Oral Abstract). APHA Annual Meeting, Philadelphia, PA.